

## Table of Contents

No.	Subject	Page No.
	<b>Chapter One</b>	1
1	Introduction	2
1.1	Cancer disease	2
1.2	Characteristics of malignant cells (cancer cells)	2
1.3	Characteristics of normal cells	3
1.4	The differences between neoplasm and their tissue of origin	3
1.5	Treatment of cancer	4
1.5.1	Signal transduction inhibitors (Kinase inhibitors)	5
1.5.1.1	Drugs in use as signal transduction inhibitors	6
1.5.1.2	Quinazolinamine (anilinoquinazoline)	6
1.5.1.2.1	Tarceva® (erlotinib)	6
1.5.1.2.2	Iressa®(Gefitinib)	7
1.5.1.2.3	Sprycel® (Dasatinib)	8
1.5.1.2.4	Gleevec® (Imatinib mesylate)	8
1.5.1.2.5	Nexavar® (Sorafenib)	9
1.5.1.2.6	Zactima® (Vandetanib)	10
1.5.1.2.7	Retaspimycin	10
1.5.1.2.8	Sutent® (Sunitinib maleate)	12
1.5.1.2.9	Istodax® (Romidepsin)	13
1.6	Angiogenesis Inhibitors	14
1.6.1	The process of angiogenesis	17
1.6.1.1	Prevascular phase of tumorigenesis (the “Angiogenic Switch”)	19
1.6.1.2	The vascular phase of tumorigenesis	19
1.6.2	Hypoxia-Driven angiogenesis	20
1.6.3	The angiogenic switch	21
1.6.4	Advantages of endothelial cells as targets of anti-tumor therapeutics	21
1.6.5	Angiogenesis inhibitors compounds	22
1.6.5.1	Endogenous angiogenesis inhibitors	22